Hadasit Bio-Holdings Ltd (HDST)

Overview

Hadasit Bio-Holdings Ltd (HBL) is a prominent entity in the biotechnology industry, located in Jerusalem, Israel. Since its incorporation in 2005, HBL has dedicated itself to innovating in the realms of oncology, regenerative medicine, and inflammatory diseases. The company’s core mission revolves around the development of biological drugs and pioneering plasma RNA biomarkers, specifically targeting colorectal cancer. Through a strategic focus on leveraging Israel's rich academic and clinical landscape, HBL aims to foster groundbreaking medical solutions that address some of the most pressing health challenges.

Products and Services

• Biological Drugs

  HBL specializes in the development of biological drugs, with a significant emphasis on creating solutions tailored to combat various cancers and chronic diseases. Leveraging advanced biotechnology research, these drugs represent the convergence of cutting-edge science and patient-centric healthcare solutions.

• Plasma RNA Biomarkers for Colorectal Cancer

  In its pursuit to advance cancer diagnostics, HBL has made strides in plasma RNA biomarker technology. This innovative approach aims to revolutionize the early detection and monitoring of colorectal cancer, offering a non-invasive and highly sensitive diagnostic tool that could significantly improve patient outcomes.

• ProtAb

  ProtAb is an immunotherapeutic monoclonal antibody developed by HBL for the treatment of autoimmune inflammatory diseases. By targeting key pathways that mediate immune response, ProtAb holds promise in providing a novel therapeutic option for patients suffering from conditions like rheumatoid arthritis and inflammatory bowel disease, amongst others.